Details for Patent: 8,003,789

Summary for Patent: 8,003,789

Title:	HIV replication inhibiting pyrimidines
Abstract:	This invention concerns the use of compounds of formula ##STR00001## the N-oxides, pharmaceutically acceptable addition salts, quaternary amines, stereochemically isomeric forms thereof, wherein -a.sup.1=a.sup.2-a.sup.3=a.sup.4- forms phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl with the attached vinyl group; n is 0 to 5; R.sup.1 is hydrogen, aryl, formyl, C.sub.1-6alkylcarbonyl, C.sub.1-6alkyl, C.sub.1-6alkyloxycarbonyl, substituted C.sub.1-6alkyl, substituted C.sub.1-6alkyloxyC.sub.1-6alkylcarbonyl; R.sup.2 is hydroxy, halo, optionally substituted C.sub.1-6alkyl, C.sub.2-6alkenyl or C.sub.2-6alkynyl, C.sub.3-7cycloalkyl, C.sub.1-6alkyloxy, C.sub.1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C.sub.1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, --S(.dbd.O).sub.pR.sup.6, --NH--S(.dbd.O).sub.pR.sup.6, --C(.dbd.O)R.sup.6, --NHC(.dbd.O)H, --C(.dbd.O)NHNH.sub.2, --NHC(.dbd.O)R.sup.6, --C(.dbd.NH)R.sup.6, 5-membered heterocyclic ring; L is optionally substituted C.sub.1-10alkyl, C.sub.2-10alkenyl, C.sub.2-10alkynyl or C.sub.3-7cycloalkyl; or --X--R.sup.3; Q is hydrogen, C.sub.1-6alkyl, halo, polyhalo-C.sub.1-6alkyl, optionally substituted amino group; Y represents hydroxy, halo, C.sub.3-7cycloalkyl, optionally substituted C.sub.1-6alkyl, C.sub.2-6alkenyl or C.sub.2-6alkynyl, C.sub.1-6alkyloxy, C.sub.1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono-or di(C.sub.1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, --S(.dbd.O).sub.pR.sup.6, --NH--S(.dbd.O).sub.pR.sup.6, --C(.dbd.O)R.sup.6, --NHC(.dbd.O)H, --C(.dbd.O)NHNH.sub.2, 13 NHC(.dbd.O)R.sup.6,--C(.dbd.NH)R.sup.6, aryl; for the treatment of subjects suffering from HIV infection.
Inventor(s):	De Corte; Bart (Southampton, PA), de Jonge; Marc Rene (Hontenissestraat, NL), Heeres; Jan (Vosselaar, BE), Ho; Chih Yung (Lansdale, PA), Janssen; Paul Adriaan Jan (Vosselaar, BE), Herwig Arts, legal representative; Frank Xavier Jozef (Brasschaat, BE), Kavash; Robert W. (Glenside, PA), Koymans; Lucien Maria Henricus (Retie, BE), Kukla; Michael Joseph (Maple Glen, PA), Ludovici; Donald William (Quakertown, PA), Van Aken; Koen Jeanne Alfons (Kuurne, BE), Marcel Andries; Koenraad Jozef Lodewijk (Beerse, BE)
Assignee:	Janssen Pharmaceutica, N.V. (BE)
Application Number:	11/930,835
Patent Claim Types: see list of patent claims	Compound; Composition; Use; Process;

Drugs Protected by US Patent 8,003,789

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 8,003,789

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	PCT/EP99/07417	Sep 24, 1999

International Family Members for US Patent 8,003,789

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1002795		PA2008016	Lithuania
European Patent Office	1002795		CA 2009 00004	Denmark
European Patent Office	1002795		300373	Netherlands
European Patent Office	1002795		91528	Luxembourg